Novelix Pharmaceuticals Limited has executed an agreement with GMBU e.V., Halle (Saale), Germany, dated 02 June 2026. This disclosure is made pursuant to Regulation 30 and Regulation 30A of the SEBI (LODR) Regulations, 2015, and in continuance of a prior submission dated 17 October 2025 (acknowledgement number 11161327).
The purpose of the agreement is the production scale-up of Astaxanthin at a commercial level at the company's research facilities in Hyderabad, India, following the success of pilot-scale production.
Key details from the annexed disclosure (as per SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026) are:
- Parties: Novelix Pharmaceuticals Limited and GMBU e.V., Halle (Saale), Germany.
- Date of Agreement: 02 June 2026.
- Shareholding: The company holds no shareholding in GMBU e.V.
- Special Rights: No special rights are agreed between the parties, including no right to appoint directors, no first right to share subscription in case of issuance of shares, and no right to restrict any change in capital structure.
- Related Party Status: The parties are not related to the promoter/promoter group/group companies of Novelix Pharmaceuticals in any manner.
- Related Party Transaction: The transaction does not fall within related party transactions.
- Issuance of Shares: Not applicable.
- Other Disclosures: Not applicable.
The document was signed by Venkateshwarlu Pulluru, Whole-time Director (DIN: 02076871), on 03 June 2026.